在线客服

晓洁:

198-8659-7060

HBL-100人整合SV40基因的乳腺上皮细胞[STR鉴定正确]

产品型号:BH-C301
产品规格:1x10^6cell/T25瓶
产品价格:¥1320

返回列表

商品详情相关试剂说明书下载参考文献

商品详情

目录号

BH-C301

细胞英文(简称)

HBL-100

细胞名称

HBL-100人整合SV40基因的乳腺上皮细胞【已通过STR鉴定】

背景资料

HBL-100是一株上皮细胞,E.V. Gaffney及其同事从一位没有乳癌家族史的供者乳汁中建立。 培养出来的细胞染色体组型在第7代时就不正常。电镜照片显示有微丝、张力原纤维和桥粒。 Southern转移表明有整合型SV40病毒基因,不可以当作正常细胞。

细胞来源

ATCC

代次

P3

规格

T25

细胞数

1x10^6 cells

生物安全级别

2

组织来源

乳腺

细胞形态

贴壁;上皮细胞样

细胞活力

95%(Viability by Trypan Blue Exclusion

细胞检测

细胞不含有HIV-1HBVHCV、支原体、细菌、酵母和真菌

培养条件

DMEM(高糖)+10% FBS(货号:C2056-1A+1%P/S37℃5% CO2

传代方法

建议1:2-1:3 两天换液一次

冻存条件

无血清细胞冻存液(货号:S002

参考文献

CLPUB00368
Polanowski F.P., Gaffney E.V., Burke R.E.
HBL-100, a cell line established from human breast milk.
In Vitro 12:328-328(1976)

PubMed=6891286; DOI=10.1007/BF00204786
Gaffney E.V.
A cell line (HBL-100) established from human breast milk.
Cell Tissue Res. 227:563-568(1982)

PubMed=6500159; DOI=10.1159/000163283
Gershwin M.E., Lentz D., Owens R.B.
Relationship between karyotype of tissue culture lines and tumorigenicity in nude mice.
Exp. Cell Biol. 52:361-370(1984)

PubMed=2995096; DOI=10.1016/0014-4827(85)90238-1
Caron de Fromentel C., Nardeux P.-C., Soussi T., Lavialle C., Estrade S., Carloni G., Chandrasekaran K., Cassingena R.
Epithelial HBL-100 cell line derived from milk of an apparently healthy woman harbours SV40 genetic information.
Exp. Cell Res. 160:83-94(1985)

PubMed=3109929; DOI=10.1016/0014-4827(87)90318-1
Dealtry G.B., Naylor M.S., Fiers W.C., Balkwill F.R.
The effect of recombinant human tumour necrosis factor on growth and macromolecular synthesis of human epithelial cells.
Exp. Cell Res. 170:428-438(1987)

PubMed=2840847
Marlhens F., Saint-Ruf C., Nardeux P.-C., Lavialle C., Brouty-Boye D., Dutrillaux B., Cassingena R.
Karyotype evolution of the human HBL-100 cell line and mapping of the integration site of SV40 DNA.
Ann. Genet. 31:81-86(1988)

PubMed=2547730; DOI=10.1002/ijc.2910440230
Saint-Ruf C., Nardeux P.-C., Cebrian J., Lacasa M., Lavialle C., Cassingena R.
Molecular cloning and characterization of endogenous SV40 DNA from human HBL-100 cells.
Int. J. Cancer 44:367-372(1989)

DOI=10.1016/B978-0-12-333530-2.50009-5
Leibovitz A.
Cell lines from human breast.
(In) Atlas of human tumor cell lines; Hay R.J., Park J.-G., Gazdar A.F. (eds.); pp.161-184; Academic Press; New York (1994)

PubMed=9671407; DOI=10.1038/sj.onc.1201814
Sweeney K.J., Swarbrick A., Sutherland R.L., Musgrove E.A.
Lack of relationship between CDK activity and G1 cyclin expression in breast cancer cells.
Oncogene 16:2865-2878(1998)

PubMed=10969801
Forozan F., Mahlamaki E.H., Monni O., Chen Y.-D., Veldman R., Jiang Y., Gooden G.C., Ethier S.P., Kallioniemi A., Kallioniemi O.-P.
Comparative genomic hybridization analysis of 38 breast cancer cell lines: a basis for interpreting complementary DNA microarray data.
Cancer Res. 60:4519-4525(2000)

PubMed=12661003; DOI=10.1002/gcc.10196
Seitz S., Wassmuth P., Plaschke J., Schackert H.K., Karsten U., Santibanez-Koref M.-F., Schlag P.M., Scherneck S.
Identification of microsatellite instability and mismatch repair gene mutations in breast cancer cell lines.
Genes Chromosomes Cancer 37:29-35(2003)

PubMed=16643607; DOI=10.1111/j.1749-0774.2005.00007.x
Yoshino K., Iimura E., Saijo K., Iwase S., Fukami K., Ohno T., Obata Y., Nakamura Y.
Essential role for gene profiling analysis in the authentication of human cell lines.
Hum. Cell 19:43-48(2006)

PubMed=17157791; DOI=10.1016/j.ccr.2006.10.008
Neve R.M., Chin K., Fridlyand J., Yeh J., Baehner F.L., Fevr T., Clark L., Bayani N., Coppe J.-P., Tong F., Speed T., Spellman P.T., DeVries S., Lapuk A., Wang N.J., Kuo W.-L., Stilwell J.L., Pinkel D., Albertson D.G., Waldman F.M., McCormick F., Dickson R.B., Johnson M.D., Lippman M.E., Ethier S.P., Gazdar A.F., Gray J.W.
A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes.
Cancer Cell 10:515-527(2006)

CLPUB00423
Morrison B.J.
Breast cancer stem cells: tumourspheres and implications for therapy.
Thesis PhD (2010), Griffith University, Australia

PubMed=20143388; DOI=10.1002/ijc.25242
Capes-Davis A., Theodosopoulos G., Atkin I., Drexler H.G., Kohara A., MacLeod R.A.F., Masters J.R.W., Nakamura Y., Reid Y.A., Reddel R.R., Freshney R.I.
Check your cultures! A list of cross-contaminated or misidentified cell lines.
Int. J. Cancer 127:1-8(2010)

PubMed=24094812; DOI=10.1016/j.ccr.2013.08.020
Timmerman L.A., Holton T., Yuneva M., Louie R.J., Padro M., Daemen A., Hu M., Chan D.A., Ethier S.P., van 't Veer L.J., Polyak K., McCormick F., Gray J.W.
Glutamine sensitivity analysis identifies the xCT antiporter as a common triple-negative breast tumor therapeutic target.
Cancer Cell 24:450-465(2013)

PubMed=24176112; DOI=10.1186/gb-2013-14-10-r110
Daemen A., Griffith O.L., Heiser L.M., Wang N.J., Enache O.M., Sanborn Z., Pepin F., Durinck S., Korkola J.E., Griffith M., Hur J.S., Huh N., Chung J., Cope L., Fackler M.J., Umbricht C., Sukumar S., Seth P., Sukhatme V.P., Jakkula L.R., Lu Y.-L., Mills G.B., Cho R.J., Collisson E.A., van 't Veer L.J., Spellman P.T., Gray J.W.
Modeling precision treatment of breast cancer.
Genome Biol. 14:R110.1-R110.14(2013)

PubMed=25485619; DOI=10.1038/nbt.3080
Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z.-S., Liu H.-B., Degenhardt J., Mayba O., Gnad F., Liu J.-F., Pau G., Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M.-M., Zynda G.J., Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L., Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J., Settleman J., Seshagiri S., Zhang Z.-M.
A comprehensive transcriptional portrait of human cancer cell lines.
Nat. Biotechnol. 33:306-312(2015)

PubMed=28889351; DOI=10.1007/s10549-017-4496-x
Saunus J.M., Smart C.E., Kutasovic J.R., Johnston R.L., Kalita-de Croft P., Miranda M., Rozali E.N., Vargas A.C., Reid L.E., Lorsy E., Cocciardi S., Seidens T., McCart Reed A.E., Dalley A.J., Wockner L.F., Johnson J., Sarkar D., Askarian-Amiri M.E., Simpson P.T., Khanna K.K., Chenevix-Trench G., Al-Ejeh F., Lakhani S.R.
Multidimensional phenotyping of breast cancer cell lines to guide preclinical research.
Breast Cancer Res. Treat. 167:289-301(2018)

联系我们
  • 19886597060